Autolus Therapeutics annual return on equity
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Autolus Therapeutics Return on Equity (ROE) Growth & History (AUTL)
Autolus Therapeutics's return on equity was −94.98% for fiscal 2025.
View full Autolus Therapeutics company overviewAutolus Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −94.98% | −13.07 pp |
| 2024 | 2024-12-31 | −81.91% | +19.70 pp |
| 2023 | 2023-12-31 | −101.61% | −52.97 pp |
| 2022 | 2022-12-31 | −48.64% | +5.66 pp |
| 2021 | 2021-12-31 | −54.30% | +6.83 pp |
| 2020 | 2020-12-31 | −61.13% | −12.59 pp |
| 2019 | 2019-12-31 | −48.54% | — |
| 2018 | 2018-09-30 | −22.78% | −0.01 pp |
| 2017 · Dec 31 | 2017-12-31 | −14.08% | — |
| 2017 · Sep 30 | 2017-09-30 | −22.77% | — |
Autolus Therapeutics quarterly return on equity
Q4.18
Q1.19
Q3.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q4.22
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −42.59% | −29.23 pp |
| Q1 2026 | 2026-03-31 | −49.90% | −32.33 pp |
| Q4 2025 | 2025-12-31 | −40.73% | −34.62 pp |
| Q3 2025 | 2025-09-30 | −25.86% | −9.52 pp |
| Q2 2025 | 2025-06-30 | −13.36% | −2.85 pp |
| Q1 2025 | 2025-03-31 | −17.57% | −2.38 pp |
| Q4 2024 | 2024-12-31 | −6.11% | +46.75 pp |
| Q3 2024 | 2024-09-30 | −16.34% | +2.80 pp |
| Q2 2024 | 2024-06-30 | −10.50% | — |
| Q1 2024 | 2024-03-31 | −15.20% | — |
| Q4 2023 | 2023-12-31 | −52.86% | −44.05 pp |
| Q3 2023 | 2023-09-30 | −19.14% | — |
| Q4 2022 | 2022-12-31 | −8.81% | — |
| Q1 2021 | 2021-03-31 | −13.06% | −2.04 pp |
| Q4 2020 | 2020-12-31 | −19.18% | −3.57 pp |
| Q3 2020 | 2020-09-30 | −15.05% | −5.46 pp |
| Q2 2020 | 2020-06-30 | −11.73% | −1.00 pp |
| Q1 2020 | 2020-03-31 | −11.02% | — |
| Q4 2019 | 2019-12-31 | −15.61% | −7.15 pp |
| Q3 2019 · Sep 30 | 2019-09-30 | −9.60% | −3.05 pp |
| Q3 2019 · Jun 30 | 2019-06-30 | −10.73% | — |
| Q1 2019 | 2018-12-31 | −8.46% | — |
| Q4 2018 | 2018-09-30 | −6.54% | — |
Autolus Therapeutics return on equity trends
Over the last five fiscal years, Autolus Therapeutics's return on equity decreased from −61.13% to −94.98%, a change of −33.85 percentage points. The latest reported quarter, Q2 2026, shows −42.59%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Autolus Therapeutics source filings ↗